GlassScriptPhysician profile
Kyaw Lyn
NPI 1902841166
$17,079.71
in general payments reported to CMS, 2019-2025
36 companies · $1,656 in 2025
The $1,656 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $1,044 · 2021: $3,264 · 2022: $3,007 · 2023: $3,394 · 2024: $3,161 · 2025: $1,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,103 · Education: $78.18 · Travel and Lodging: $28.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,103.46 |
| Education | $78.18 |
| Travel and Lodging | $28.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,587.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,960.00 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $1,449.93 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,318.04 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,158.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $1,072.09 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $790.07 | 2019-2024 | Verquvo, Vaxneuvance, Pneumovax 23 |
| Glaxosmithkline, LLC. | $739.26 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $451.54 | 2020-2025 | Nexletol |
| Pfizer INC. | $397.99 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $321.59 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $256.76 | 2021-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.52 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $230.90 | 2019-2022 | |
| Corcept Therapeutics | $173.97 | 2024-2025 | Korlym |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $167.62 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $165.45 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $154.57 | 2019-2024 | |
| Abbott Laboratories | $150.00 | 2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $149.98 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $135.79 | 2022-2025 | Gvoke Hypopen |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2022 | |
| Aimmune Therapeutics, INC. | $124.98 | 2024 | |
| Urovant Sciences INC | $114.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.42 | 2020-2024 | Trintellix |
| Sumitomo Pharma America, INC. | $101.73 | 2024-2025 | Gemtesa |
| Mylan Specialty L.P. | $52.01 | 2021-2023 | Yupelri |
| Abbvie INC. | $48.12 | 2021 | |
| Astellas Pharma US INC | $48.03 | 2019-2023 | Veozah |
| Allergan, INC. | $38.20 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $35.63 | 2022 | |
| Mannkind Corporation | $20.35 | 2020 | |
| Edwards Lifesciences Corporation | $19.76 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Hikma Pharmaceuticals USA | $19.29 | 2023 | Ryaltris, Mitigare |
| Smith+Nephew, INC. | $14.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyaw Lyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.